Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction

      The hypothesis that aspirin resistance is often due to noncompliance was investigated. One hundred ninety patients with a history of myocardial infarction were evaluated using arachidonic acid–stimulated light aggregometry at 3 different time points: while receiving their usual daily aspirin, after not receiving aspirin for 7 days, and 2 hours after the observed ingestion of aspirin 325 mg. At the first time point, 17 patients (9%) failed to show aspirin inhibition of platelet aggregation, but 2 hours after observed aspirin ingestion, aspirin inhibition was observed in all but 1 patient.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cotter G.
        • Shemesh E.
        • Zehavi M.
        • Dinur I.
        • Rudnick A.
        • Milo O.
        • Vered Z.
        • Krakover R.
        • Kaluski E.
        • Kornberg A.
        Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?.
        Am Heart J. 2004; 147: 293-300
        • Schwartz K.A.
        • Schwartz D.E.
        • Pittsley R.A.
        • Mantz S.L.
        • Ens G.
        • Sami A.
        • Davis J.M.
        A new method for measuring inhibition of platelet function by nonsteroidal antiinflammatory drugs.
        J Lab Clin Med. 2002; 139: 227-233
        • Neter J.
        • Kutner M.
        • Nachtsheim C.
        • Wasserman W.
        Applied Linear Statistical Models.
        Irwin, Chicago1996
        • Gum P.A.
        • Kottke-Marchant K.
        • Welsh P.A.
        • White J.
        • Topol E.J.
        A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.
        J Am Coll Cardiol. 2003; 41: 961-965
        • Eikelboom J.W.
        • Hirsh J.
        • Weitz J.I.
        • Johnston M.
        • Yi Q.
        • Yusuf S.
        Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.
        Circulation. 2002; 105: 1650-1655
        • Grotemeyer K.H.
        • Scharafinski H.W.
        • Husstedt I.W.
        Two-year follow-up of aspirin responder and aspirin non responder.
        Thromb Res. 1993; 71: 297-403
        • Tamminen M.
        • Lassila R.
        • Westerbacka J.
        • Vehkavaara S.
        • Yki-Jarvinen H.
        Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects.
        Int J Obes Relat Metab Disord. 2003; 27: 907-911
        • Friend M.
        • Vucenik I.
        • Miller M.
        Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia.
        BMJ. 2003; 326: 82-83
        • Sane D.C.
        • McKee S.A.
        • Malinin A.I.
        • Serebruany V.L.
        Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin.
        Am J Cardiol. 2002; 90: 893-895
        • Mori T.A.
        • Vandongen R.
        • Andrea D.J.
        • Mcculloch R.K.
        • Burke V.
        Differential effect of aspirin on platelet aggregation in IDDM.
        Diabetes. 1992; 41: 261-266